Bortezomib

Therapeutic Group

Indication Dosage

Bortezomib is a medication used to treat a type of blood cancer called multiple myeloma. It is also prescribed for certain cases of another blood disorder called mantle cell lymphoma when other treatments have not worked. Bortezomib helps slow down the growth of cancer cells and can improve the quality of life for people with these conditions.

Multiple Myeloma, Mantle Cell Lymphoma:

By IV Inj, Or By Sc Inj:

Adult: Specialist Use Only. (consult Product Literature Or Local Protocols)

Content

Inj 3.5mg: Bortezomib 3.5mg

Pregnancy

Use Only If Essential

Stability

Antineoplastic Drugs, Proteasome Inhibitors

Contra Indications

Acute Diffuse Infiltrative Pulmonary Disease, Pericardial Disease

Precautions

Acute Diffuse Infiltrative Pulmonary Disease, Pericardial Disease

Lactation

Avoid. Discontinue Breast-feeding.

Side Effects

Anaemia
Anxiety
Arrhythmias
Asthenia
Chills
Constipation
Decreased Leucocytes
Diabetes Mellitus
Diarrhoea
Dizziness
Dysphagia
Dyspnoea
Electrolyte Imbalance
Encephalopathy
Enzyme Abnormality
Eye Inflammation
Fever
Fluid Imbalance
Gi Disorder
Haemorrhage
Hair Disorder
Headaches
Hearing Impairment
Heart Failure
Hepatic Disorders
Hiccups
Hyperbilirubinaemia
Hypersensitivity
Hypertension
Hypotension
Ischaemic Heart Disease
Lethargy
Loss Of Consciousness
Confusion
Malaise
Nausea
Nerve Disorders
Neuromuscular Dysfunction
Neutropenia
Oedema
Oral Disorders
Oropharyngeal Complaints
Pain
Renal Impairment
Sepsis
Syncope
Thrombocytopenia
Tinnitus
Ventricular Dysfunction
Vertigo
Vision Disorders
Vomiting.
Rare: Angioedema
Cardiovascular Disorders
Cerebrovascular Insufficiency
Posterior Reversible Encephalopathy Syndrome (pres) (discontinue)
Proteinuria
Psychiatric Disorders
Acidosis
Acute Coronary Syndrome
Blood Disorders
Bone Disorder
Brain Oedema
Cns Haemorrhage
Cognitive Disorder
Coma
Sudden Death
Suicidal Ideation
Herpes Zoster Reactivation
Progressive Multifocal Leukoencephalopathy (pml)